CHECKLIST FOR THE SAFEST USE OF DABIGATRAN, RIVAROXABAN & APIXABAN IN ATRIAL FIBRILLATION: INCLUSION & EXCLUSION CRITERIA

被引：0
|
作者：
Leong, Wendy A. [1 ,2 ]
机构：
[1] Burnaby Res Vancouver, Vancouver, BC, Canada
[2] Univ British Columbia Vancouver, Vancouver, BC, Canada
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2014年 / 89卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
180
引用
收藏
页码：E86 / E86
页数：1
相关论文
共 50 条
  • [41] Safety of apixaban and rivaroxaban in patients with atrial fibrillation on hemodialysis
    Ito, Hiroshi
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2024, 124 : 154 - 155
  • [42] Value-based pricing for dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation in Germany
    Krejczy, M.
    Marx, S.
    Obermann, K.
    Wehling, M.
    Harenberg, J.
    EUROPEAN HEART JOURNAL, 2012, 33 : 815 - 815
  • [43] EVALUATION OF HEALTHCARE COSTS OF ELDERLY NONVALVULAR ATRIAL FIBRILLATION PATIENTS TREATED WITH APIXABAN VS. RIVAROXABAN AND DABIGATRAN
    Deitelzweig, S.
    Luo, X.
    Gupta, K.
    Trocio, J.
    Mardekian, J.
    Curtice, T.
    Lingohr-Smith, M.
    Menges, B. L.
    Lin, J.
    VALUE IN HEALTH, 2017, 20 (05) : A266 - A266
  • [44] Value-based pricing for dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation in Germany
    Krejczy, Martin
    Marx, Svetlana
    Obermann, Konrad
    Wehling, Martin
    Harenberg, Job
    THROMBOSIS RESEARCH, 2012, 130 : S100 - S100
  • [45] Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study
    Kjerpeseth, Lars J.
    Selmer, Randi
    Ariansen, Inger
    Karlstad, Oystein
    Ellekjaer, Hanne
    Skovlund, Eva
    PLOS ONE, 2019, 14 (08):
  • [46] Secondary Prevention Dabigatran and Rivaroxaban in Atrial Fibrillation and Dialysis
    不详
    AKTUELLE NEUROLOGIE, 2015, 42 (06) : E82 - E82
  • [47] Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis
    Harenberg, J.
    Marx, S.
    Diener, H. -C.
    Lip, G. Y. H.
    Marder, V. J.
    Wehling, M.
    Weiss, C.
    INTERNATIONAL ANGIOLOGY, 2012, 31 (04) : 330 - 339
  • [48] COST-EFFECTIVENESS OF EDOXABAN, APIXABAN, RIVAROXABAN AND DABIGATRAN VERSUS WARFARIN FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION
    Marchetti, M.
    Liberato, N. L.
    Rognoni, C.
    Quaglini, S.
    HAEMATOLOGICA, 2014, 99 : 487 - 487
  • [49] HOSPITAL READMISSIONS AMONG PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION TREATED WITH THE NEW ORAL ANTICOAGULANTS, APIXABAN, DABIGATRAN, AND RIVAROXABAN
    Deitelzweig, Steven
    Gupta, Kiran
    Nadkarni, Anagha
    Trocio, Jeffrey
    Lin, Jay
    Lingohr-Smith, Melissa
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 805 - 805
  • [50] COST EFFECTIVENESS EVALUATION OF APIXABAN, DABIGATRAN RIVAROXABAN AND WARFARIN FOR PREVENTION OF TROMBOEMBOLISM IN PATIENTS WITH ATRIAL FIBRILLATION IN TRINIDAD AND TOBAGO
    Garita, M.
    Peralta, M.
    Dookie, T. A.
    VALUE IN HEALTH, 2014, 17 (03) : A116 - A117
12345